Women value non-surgical treatment options for tubal ectopic pregnancy (tEP). Current medical treatment (with a drug called methotrexate) has up to a 30% failure rate whereby women will still require emergency surgery. This trial will investigate if adding mifepristone to standard medical treatment reduces the need for emergency surgery for tEP in women clinically suitable for medical management of tEP.
The AMETHYST study is an NIHR funded study comparing a combination of MTX and mifepristone versus MTX alone as a medical treatment for tubal ectopic pregnancy with the primary aim of reducing the need for surgical intervention.
As a UK based study, AMETHYST aims to run for 44 months (approx. end July 2028) and recruit 328 women aged 16 years and older who are deemed suitable clinically (haemodynamically stable) and who opt for medical treatment using MTX for an ultrasonically suspected tubal ectopic pregnancy (tEP) with an hCG level of 1000 to 5000 IU/L.
AMETHYST is led by Dr Andrea Woolner, based at the University of Aberdeen.
Please click here to access the AMETHYST Expression of Interest Form.
Contacts
- Claire Cochran; claire.cochran@abdn.ac.uk